Paul J. Sekhri, Director at Apnimed, Inc. (APMD), bought 12,500 shares at $16.00 ($200K) on 2026-08-03, disclosed to the SEC on 2026-08-03.
Director Paul J. Sekhri purchased $200,000 worth of shares at $16.00, marking the largest insider purchase in the company's history and signaling strong conviction in the stock's potential. This significant accumulation comes at a time when the stock is trading near its 52-week low, potentially offering an attractive entry point for aggressive investors.
The stock is currently trading at $25.05, which is 12.04% below its 52-week high of $28.48 and 54.34% above its 52-week low of $16.23. The stock has recently gained visibility after being added to the NASDAQ Composite Index on August 14, 2026.
1) NASDAQ Composite Index inclusion on August 14, 2026, which increases visibility and liquidity for index-tracking funds. 2) The largest insider purchase in company history, indicating strong insider conviction. 3) The stock is currently trading 54.34% above its 52-week low of $16.23, presenting a potential value opportunity.
1) The stock is currently trading at a premium to its 52-week low, which could limit further upside if the company fails to meet market expectations. 2) The stock is trading at a high price-to-earnings ratio of 9.18, which may be unsustainable if earnings growth slows.
Nothing distinguishes this filing.
| Filing → |
| VEEV | SELL | 2023-03-06 | $484K | — | Filing → |
| VEEV | SELL | 2022-04-01 | $2.4M | — | Filing → |
| PHGE | BUY | 2021-07-30 | $50K | — | Filing → |